Cabazitaxel
Brand names: Jevtana
Cabazitaxel is an intravenous taxane chemotherapy used, with prednisolone, for metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds tubulin and stabilises microtubules, preventing depolymerisation and arresting cell division; it is a poor substrate for P-glycoprotein, retaining activity in docetaxel-resistant disease.
Prescribing in practice
- Severe neutropenia and febrile neutropenia are major risks and can be fatal, so blood counts are monitored and granulocyte colony-stimulating factor prophylaxis is considered, especially in higher-risk patients.
- Hypersensitivity reactions can occur, so premedication with antihistamine, corticosteroid and an H2 antagonist is given.
- Diarrhoea, which may be severe, and nausea require active management and fluid replacement.
Monitoring
Monitor the full blood count before each cycle, together with hydration status, renal and hepatic function and signs of infection.
Counselling the patient
- Report fever or any sign of infection, or severe diarrhoea, urgently.
- Take the accompanying steroid as directed and attend all blood-test appointments.
Evidence & guidelines
Use is supported by a randomised controlled trial showing a survival benefit after docetaxel and by NICE guidance.
Reference: NICE TA391; ESMO; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.